Angiotensin II, RAS Activation, and RAS Blockers in COVID-19: Unambiguous Evidence.

Calò, Lorenzo A; Stefanelli, Lucia Federica; Nalesso, Federico

Calò, Lorenzo A; Stefanelli, Lucia Federica; Nalesso, Federico.

Calò LA; Nephrology, Dialysis and Transplantation Unit, Department of Medicine, University of Padova, Padova, Italy.
Stefanelli LF; Nephrology, Dialysis and Transplantation Unit, Department of Medicine, University of Padova, Padova, Italy.
Nalesso F; Nephrology, Dialysis and Transplantation Unit, Department of Medicine, University of Padova, Padova, Italy.

Kidney Blood Press Res ; 47(10): 593-596, 2022.

Article in English | MEDLINE | ID: covidwho-2020587

Subject(s)

Bartter Syndrome; COVID-19; Humans; Angiotensin II

Keywords

Angiotensin II; Bartter's syndrome; COVID-19; Gitelman's syndrome; RAS blockers

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Bartter Syndrome / COVID-19 Limits: Humans Language: English Journal: Kidney Blood Press Res Journal subject: Nephrology Year: 2022 Document Type: Article Affiliation country: 000526791

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google